MétaCan
Menu
Back to cohort
Record W4322757424 · doi:10.1037/hea0001253

Fear of cancer recurrence therapy (FORT): A randomized controlled trial.

2023· article· en· W4322757424 on OpenAlexafffund
Christine Maheu, Sophie Lebel, Lori J. Bernstein, Christine Courbasson, Mina Singh, Sarah Ferguson, Cheryl Harris, Lynne Jolicoeur, Lorena Baku, Linda Muraca, Agnihotram V. Ramanakumar, Frederic Lamonde, Monique Lefèbvre, Christina Tomei, Brittany Mutsaers, Scott Secord, Joanne Power, Nancy Drummond, Maude Hébert, Rajvi J. Wani

Bibliographic record

VenueHealth Psychology · 2023
Typearticle
Languageen
FieldMedicine
TopicCancer survivorship and care
Canadian institutionsOntario Medical AssociationMcGill University Health CentreUniversity of WaterlooUniversité du Québec à Trois-RivièresCanadian Association of Psychosocial OncologyYork UniversityOttawa HospitalPrincess Margaret Cancer CentreJewish General HospitalUniversity of OttawaMcGill University
FundersCanadian Cancer Society Research InstituteRéseau de recherche portant sur les interventions en sciences infirmières du QuébecMcGill University
KeywordsMedicineRandomized controlled trialBreast cancerPhysical therapyPsychological interventionCoping (psychology)PsycINFODistressQuality of life (healthcare)Cognitive behavioral therapyCognitive therapyCancerInternal medicineClinical psychologyMEDLINEPsychiatryNursing

Abstract

fetched live from OpenAlex

OBJECTIVE: Most fear of cancer recurrence (FCR) interventions have small effects, and few target FCR. This randomized controlled trial (RCT) with breast and gynecological cancer survivors evaluated the efficacy of a cognitive-existential fear of recurrence therapy (FORT) compared to an attention placebo control group (living well with cancer [LWWC]) on FCR. METHOD: One hundred and sixty-four women with clinical levels of FCR and cancer distress were randomly assigned to 6-weekly, 120 min FORT (n = 80) or LWWC (n = 84) group sessions. They completed questionnaires at baseline (T1), posttreatment (T2; primary endpoint), 3 (T3), and 6 months (T4) posttreatment. Generalized linear models were used to compare group differences in the fear of cancer recurrence inventory (FCRI) total score and secondary outcomes. RESULTS: FORT participants experienced greater reductions from T1 to T2 on FCRI total with a between-group difference of -9.48 points (p = .0393), resulting in a medium effect of -0.530, with a maintained effect at T3 (p = .0330) but not at T4. For the secondary outcomes, improvements were in favor of FORT, including FCRI triggers (p = .0208), FCRI coping (p = .0351), cognitive avoidance (p = .0155), need for reassurance from physicians (p = .0117), and quality of life (mental health; p = .0147). CONCLUSIONS: This RCT demonstrated that FORT, compared to an attention placebo control group, resulted in a greater reduction in FCR posttreatment and at 3 months posttreatment in women with breast and gynecological cancer, indicating its potential as a new treatment strategy. We recommend a booster session to sustain gains. (PsycInfo Database Record (c) 2023 APA, all rights reserved).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.011
Threshold uncertainty score0.036

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.005
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0110.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.070
GPT teacher head0.472
Teacher spread0.401 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations39
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueHealth PsychologySame topicCancer survivorship and careFrench-language works237,207